Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,286 papers from all fields of science
Search
Sign In
Create Free Account
Stage IV Bladder Cancer AJCC v6
Known as:
carcinoma of the bladder, stage IV
, Jewett-Marshall Stage D Urinary Bladder Cancer
, bladder cancer, metastatic
Expand
Stage IV includes the following: T4b, N0, M0; Any T, N1, M0; Any T, N2 M0; Any T, N3 M0; Any T, Any N, M1. T4b: Tumor invades the pelvic wall…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Epithelial Cells
Epithelium
Hematuria
Malignant Epithelial Cell
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy?
K. Ogihara*
,
E. Kikuchi
,
+10 authors
M. Oya
OncoTarget
2017
Corpus ID: 8359661
We investigated whether the concept of oligometastasis may be introduced to the clinical management of metastatic bladder cancer…
Expand
2014
2014
The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
Yong-tong Zhu
,
Zhen Zhao
,
+7 authors
Wan-long Tan
Stem Cell Research
2014
Corpus ID: 45294793
Review
2014
Review
2014
Optimal Treatment for Metastatic Bladder Cancer
E. Carballido
,
J. Rosenberg
Current Oncology Reports
2014
Corpus ID: 38492262
Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine…
Expand
Review
2010
Review
2010
[Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
A. Stenzl
,
Nigel C. Cowan
,
+6 authors
J. Witjes
Actas Urológicas Españolas
2010
Corpus ID: 21586159
Review
2009
Review
2009
The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target.
Steven C. Smith
,
D. Theodorescu
Urologic oncology
2009
Corpus ID: 21910626
Review
2008
Review
2008
Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways
H. Wallerand
,
Robert R Reiter
,
A. Ravaud
Current Opinion in Urology
2008
Corpus ID: 25030283
Purpose of review An estimated 300 000 new cases of bladder cancer worldwide are diagnosed annually. Although new cytotoxic…
Expand
Highly Cited
2007
Highly Cited
2007
Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis
P. Bassi
,
E. Sacco
,
V. De Marco
,
M. Aragona
,
A. Volpe
BJU International
2007
Corpus ID: 30859131
To compare the prognostic performance of an artificial neural network (ANN) with that of standard logistic regression (LR), in…
Expand
2007
2007
Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study
P. Beuzeboc
,
E. Banu
,
+7 authors
S. Oudard
2007
Corpus ID: 78444232
15565 Background: Almost 25% of BC patients overexpressed HER2 and 50 to 60% of them are responding to the combination of T with…
Expand
1981
1981
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
R. Smalley
,
R. Smalley
,
+5 authors
M. Hester
Journal of Urology
1981
Corpus ID: 29820144
Highly Cited
1980
Highly Cited
1980
Chemotherapy of Metastatic Bladder Cancer
A. Yagoda
Cancer
1980
Corpus ID: 4507795
Recent disease‐oriented phase II clinical trials in advanced transitional cell carcinoma of the urothelial tract have defined the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required